Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $5.33.
Several research analysts have recently weighed in on CGEN shares. Stifel Nicolaus lifted their target price on shares of Compugen from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, December 19th. StockNews.com downgraded shares of Compugen from a “hold” rating to a “sell” rating in a research report on Thursday.
Institutional Trading of Compugen
Compugen Price Performance
Shares of CGEN opened at $2.42 on Tuesday. The firm’s 50 day moving average is $1.53 and its 200-day moving average is $1.15. The stock has a market capitalization of $209.62 million, a P/E ratio of -6.54 and a beta of 2.80. Compugen has a 12-month low of $0.53 and a 12-month high of $2.69.
Compugen (NASDAQ:CGEN – Get Free Report) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). As a group, equities research analysts forecast that Compugen will post -0.34 EPS for the current fiscal year.
Compugen Company Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Five stocks we like better than Compugen
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 5 best stocks to buy in a bear market
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 2 REIT stocks set to surge due to red hot data center demand
- Insider Selling Explained: Can it Inform Your Investing Choices?
- How and when to use LEAPS stock options
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.